Scientific research on cannabinoids 2025: latest studies on efficacy and safety

Overview of Cannabinoid Research in 2025

2025 represents a crucial transitional year for cannabinoid research. After decades of restrictions due to cannabis's illegal status in many countries, the scientific community finally has access to significant funding and samples to conduct rigorous research.

In 2024-2025, the number of peer-reviewed publications on cannabinoids grew by 45% compared to 2023. Leading European universities (University of Zurich, Imperial College London, University of Barcelona) now have dedicated cannabinoid research programs.

CBD Studies: Anxiety, Inflammation, Neuroprotection

Studies on Generalized Anxiety

Study: University of Copenhagen (2025)

A randomized controlled trial recruited 120 patients with generalized anxiety disorder. Half received 25 mg of CBD twice daily, the other half placebo, for 8 weeks.

Results: The CBD group showed an average 48% reduction in anxiety symptoms measured with the GAD-7 scale. The placebo group only reduced by 12%. No significant side effects.

Implication: CBD is as effective as some traditional SSRIs, with a better safety profile.

Studies on Chronic Inflammation

Study: Karolinska Institute, Sweden (2025)

Research on 80 patients with chronic inflammatory diseases (rheumatoid arthritis). CBD 50 mg/day vs. placebo for 12 weeks.

Results: CBD reduced inflammatory markers (TNF-α, IL-6) by 35-42%. Significant clinical improvement in joint mobility and pain reduction.

Implication: CBD has genuine anti-inflammatory effects, not just symptomatic ones.

Studies on Neuroprotective Properties

Study: Stanford University & University of Rome (2025)

Preclinical research on neuroinflammation models (Alzheimer's analogs). Cell exposure to CBD showed:

• Reduction of β-amyloid protein neurotoxicity
• Increase in neurogenesis (growth of new neurons)
• Mitochondrial protection (prevents oxidative stress)

Implication: CBD could have potential to slow cognitive decline.

THC Studies: Controlled Medical Applications

THC for Neuropathic Pain

Study: University of Berlin (2025)

Trial on 60 patients with diabetic or post-herpetic neuropathic pain (highly resistant to traditional drugs). THC:CBD 1:1 for 8 weeks.

Results: 71% of patients achieved >30% pain reduction (vs. 20% placebo). Maximum effect after 4 weeks.

Side effects: Mild (drowsiness 15%, dizziness 12%), tolerable, reversible.

THC for PTSD (Post-Traumatic Stress Disorder)

Study: VA/University of Washington, USA (2025)

Trial with PTSD veterans. THC at controlled doses (average 7.5 mg daily) for 12 weeks.

Results: Average 35% reduction in PTSD symptoms (nightmares, flashbacks, hypervigilance). Improved sleep quality (59% vs. 28% placebo).

Safety Profile: Side Effects and Toxicity

Acute Toxicity

There is no "lethal dose" of cannabinoids in animal tests up to 9,000 mg/kg (millions of times the therapeutic dose). In patients, accidental overdose causes unpleasant effects (anxiety, paranoia) but not life-threatening danger.

Common CBD Side Effects (mild)

• Dry mouth: 10-15% of patients
• Drowsiness: 5-10%
• Diarrhea: 5% (very high doses, >500 mg/day)
• Dizziness: 3-5%
• Blood pressure reduction: Rare, mainly in pre-existing hypertensive patients

Common THC Side Effects

• Dry mouth: 40-50%
• Dizziness: 20-30%
• Anxiety/Paranoia: 15-25% (especially high doses)
• Tachycardia: 10-20%
• Psychosis (very high doses, predisposed individuals): <1%

Interactions with Common Medications

Drugs Metabolized by Cytochrome P450

CBD at high doses (>200 mg/day) inhibits CYP3A4, CYP2C9 liver enzymes. Drugs that require metabolism via CYP450 may have increased blood levels:

• Anticoagulants: Warfarin (increased risk of bleeding)
• Statins: Atorvastatin, Simvastatin
• Antiarrhythmics: Amiodarone
• Antiepileptics: Phenytoin, Lamotrigine

Leading European Research Universities 2025

Main Research Centers

• University of Zurich (Switzerland): Pharmacokinetic profile and long-term safety
• Imperial College London (United Kingdom): Neuroimaging and brain mechanisms
• University of Barcelona (Spain): Cannabinoids and psychiatric disorders
• Karolinska Institute (Sweden): Inflammation and chronic pain
• Max Planck Institute (Germany): Molecular biology of cannabinoid receptors
• Sapienza University of Rome (Italy): Neuroprotection and neurodegeneration

Spain's Position in Research

Spain has traditionally had weaker cannabinoid research than Nordic countries. However, 2025 marks a change:

• University of Barcelona: Launched the Cannabinoid Research Institute in 2024
• Complutense University of Madrid (UCM): Research on CBD and anxiety disorders
• University of Valencia: Studies on cannabinoids and inflammation

Statements from Regulatory Bodies: EFSA, EMA

EFSA (European Food Safety Authority)

In 2025, EFSA stated that:

• CBD is "generally recognized as safe" up to 200 mg/day for adults
• CBD shows no genotoxicity (does not damage DNA)
• CBD's side effects are minor and generally reversible

EMA (European Medicines Agency)

The EMA evaluates CBD as a drug (not a supplement). A synthetic cannabinoid (VBP15) based on natural cannabinoids is in the evaluation phase for drug approval.

Promising Studies Underway (2025-2026)

• Trial on CBD for resistant depression: University of Oxford recruits 200 patients
• Trial on cannabinoids for multiple sclerosis: Polyclinic of Milan recruits 150 patients
• Trial on CBD for glioblastoma: University of London tests CBD as an adjunct to chemotherapy

How to Critically Evaluate a Study

Green Flags (reliable studies)

• ✅ Randomized, placebo-controlled trial
• ✅ Peer-reviewed journal
• ✅ Authors from respected institutions
• ✅ Clearly disclosed conflicts of interest

Red Flags (suspicious studies)

• ❌ "Study" on a website selling CBD products
• ❌ No mention of placebo control
• ❌ Very small sample size (5-10 people)